Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18:13:1041356.
doi: 10.3389/fimmu.2022.1041356. eCollection 2022.

Association of mean platelet volume/lymphocyte ratio with inflammation in non-dialysis patients with chronic kidney disease stages 1-4: A retrospective study

Bei Xu  1 , Yamei Zhang  1 , Gang Chen  1 , Jiafu Feng  1 , Lingling Gan  1
Affiliations

Association of mean platelet volume/lymphocyte ratio with inflammation in non-dialysis patients with chronic kidney disease stages 1-4: A retrospective study

Bei Xu et al. Front Immunol. .

Abstract

Objective: The mean platelet volume/ratio (MPVLR) is recognized as a novel marker of inflammation. We evaluated whether the MPVLR is associated with inflammation in non-dialysis patients with chronic kidney disease (CKD) stages 1-4.

Methods: A total of 402 non-dialysis patients with CKD stages 1-4 were included. The indicators of hematological, renal function (urea, serum creatinine [Scr], estimated glomerular filtration rate [eGFR], and urine albumin to creatinine ratio [ACR]) and the markers of inflammation (high-sensitivity C-reactive protein [hsCRP] and fibrinogen [FIB]) were recorded. The MPVLR values at different CKD stages were analyzed. Next, based on the absence (hsCRP level < 5 mg/L) and presence (hsCRP level > 5 mg/L) of inflammation, the patients were categorized, and the differences in indices between the two groups were observed. The patients were divided into two groups based on the median MPVLR value (6.39) at admission. The laboratory indices of patients with CKD were compared. Simultaneously, a correlation analysis was performed to identify the association between the MPVLR and each parameter. A binary logistic regression analysis was performed to test whether the MPVLR was associated independently with the presence of inflammation in non-dialysis patients with CKD. The receiver operating characteristic (ROC) curve was used to analyzed diagnostic performance of the MPVLR in evaluating the inflammation of non-dialysis patients with CKD stages 1-4.

Results: The MPVLR was higher in patients with CKD stages 3-4 than in those with CKD stages 1 and 2. Significant differences in urea, Scr, eGFR, ACR, lymphocyte (LYM), red blood cell (RBC), hemoglobin (HGB), RBC distribution width (RDW-CV), MPVLR, and FIB values were observed between the groups with and without inflammation. The patients with a higher MPVLR had higher urea, Scr, ACR, WBC, neutrophils (NEU), RDW-CV, platelet distribution width (PDW), mean platelet volume (MPV), and hsCRP values and lower eGFR, LYM, RBC, HGB, and platelet (PLT) values. The MPVLR showed a positive correlation with age, urea, Scr, WBC, NEU, RDW-CV, PDW, MPV, and hsCRP values and a negative correlation with the eGFR, LYM, RBC, HGB, and PLT values. A logistic analysis revealed that the MPVLR was associated independently with the presence of inflammation in non-dialysis patients with CKD, after adjustment for the confounding factors (odds ratio = 1.020; P = 0.024). Furthermore, MPVLR exhibited a modest diagnostic performance for the assessment of inflammation in non-dialysis patients with CKD stages 1-4, with an area under the curve (AUC) of 0.706, and the sensitivity, specificity being 46.2% and 83.2%, respectively.

Conclusions: The MPVLR was associated independently with the presence of inflammation in non-dialysis patients with CKD and may be useful for monitoring inflammation.

Keywords: chronic kidney disease; inflammation; kidney; mean platelet volume/lymphocyte ratio; non-dialysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that may be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study design and the patient categorization.
Figure 2
Figure 2
The level of MPVLR across CKD stages 1−4.
Figure 3
Figure 3
Diagnostic efficacy of MPVLR in the evaluation of the inflammation in non-dialysis patients with CKD stages 1–4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Guan Y, Liang X, Ma Z, Hu H, Liu H, Miao Z, et al. . A single genetic locus controls both expression of DPEP1/CHMP1A and kidney disease development via ferroptosis. Nat Commun (2021) 12(1):5078. doi: 10.1038/s41467-021-25377-x - DOI - PMC - PubMed
    1. Levin ASP, Bilous R, Coresh J, Coresh J, de Francisco ALM, de Jong PE, et al. . KDIGO 2012 clinical practice guideline for the evaluation management of chronic kidney disease. chapter 1: Definition classification of CKD. kidney. Int Suppl (2013) 3:19–62. doi: 10.1038/kisup.2012.64 - DOI - PubMed
    1. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. . Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol (2012) 7(12):1938–46. doi: 10.2215/CJN.03500412 - DOI - PMC - PubMed
    1. Kraynak TE, Marsland AL, Wager TD, Gianaros PJ. Functional neuroanatomy of peripheral inflammatory physiology: A meta-analysis of human neuroimaging studies. Neurosci Biobehav Rev (2018) 94:76–92. doi: 10.1016/j.neubiorev.2018.07.013 - DOI - PMC - PubMed
    1. Vaziri ND, Liu SM, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, et al. . High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PloS One (2014) 9(12):e114881. doi: 10.1371/journal.pone.0114881 - DOI - PMC - PubMed

Publication types